Sutekast Capsule

Sutekast Salt is an indolinone simulator and tyrosine inhibitor with latent antineoplastic activity. Sunitinib Malate blocks the activity of vascular endothelial kinase 2 (VEGFR2) receptors, platelets - producing growth factor b (PDGFRb) and c-kit receptors, which limit angiogenesis and cell proliferation. These mediators also counteract the phosphorylation of tyrosine kinase 3 associated with Fms (FLT3), another tyrosine kinase receptor articulated by some leukemia cells.

This salt was originally approved in the United States in 2006. Since, the expiration of the US patent, it has been manufactured and used in India.

How does Sutekast (Sunitinib Malate) work?

Sutekast (Sunitinib Malate) prevents the movement of multiple receptor tyrosine kinases (RTKs). These include all platelet-derived growth function receptors (PDGF-Rs) and vascular endothelial growth function receptors (VEGFR), which play important roles in tumor cell proliferation and angiogenesis. Therefore, direct reserve of this target reduces tumor vascularization and activates apoptosis of cancer cells, thereby causing tumor shrinkage.

This salt also prevents CD117 (c-KIT), a tyrosine kinase receptor which (if not properly activated by alteration) supplies energy to the main stream of intestinal stromal cell tumor. It is recommended as second-line therapy for patients whose tumors have increased c-KIT mutations, which make imatinib infection more difficult, or who cannot tolerate the drug.

In addition, sunitinib confuses other compromised receptors:

• RET

• CD135

• CD114

Sutekast (Sunitinib Malate) targets multiple receptors that cause various side effects, such as classic arm and leg syndrome, stomatitis, and other dermatological toxicities.

Usage and Indications

It is a kinase inhibitor used to treat:

Gastrointestinal stromal tumor (GIST) after disease that develops on imatinib mesylate or is affected by imatinib mesylate
Progressive and well-differentiated neuroendocrine pancreatic tumor (pNET) in patients with inoperable metastatic or advanced disease.
Advanced Renal Cell Carcinoma (RCC)

Dosage & Administration

Recommended dosage for adjuvant treatment of RCC

The scheduled dose of Sutekast (Sunitinib Malate) for adjuvant RCC treatment is 50 mg orally once daily with a one-month treatment schedule, followed by 15 days off for a six-week cycle. Sutekast can be consumed with or without food.

Recommended dosage for pNET

The recommended dose for pNET (a progressive and well-differentiated neuroendocrine pancreatic tumor) is 37.5 mg orally daily. Continuously without a scheduled off-treatment period. Patients can take it with or without food.

Dosage Forms & Strengths

12.5 mg capsule

Hard jelly capsule with orange cap and orange body, with the stamp "Sutekast" on the lid and "SUTEKAST 12.5 mg" on the body.

25 mg capsule

Hard jelly capsules with caramel caps and orange body, with the stamp "Sutekast" on the lid and SUTEKAST-25 - Sutekast capsules 25 mg on the body.

50 mg capsule

Hard jelly capsules with caramel caps and orange body, with the brand "Sutekast" on the lid and SUTEKAST-50 - Sutekast 50 mg capsules on the body.

Side Effects

Sunitinib Malate Capsule is measured in a controllable manner and the incidence of side effects is extremely low.

The most common side effects of sunitinib (Sunitinib Malate) therapy are diarrhea, nausea, fatigue, yellowing of the skin, high blood pressure, stomatitis, and skin reactions on the hands and feet. During Phase III placebo-controlled GIST studies, side effects often included asthenia, change in taste, constipation, skin discoloration, diarrhea, stomatitis, and anorexia.

Dose reductions were required in more than 50% of patients tested at the RCC to overcome the important toxicity of this compound.

Extreme frequency (Grade 3 or 4) occurs in ≤ 10% of patients and includes diarrhea, high blood pressure, fatigue and chemotherapy-induced acrylic erythema. Laboratory abnormalities associated with Sutekast's therapy include amylase, lipase, platelets, lymphocytes, and neutrophils. Reversible erythrocytosis and hypothyroidism are also associated with it.

It can control most unpleasant events through maintenance therapy, dose discontinuation, or dose reduction.

Warnings & Precautions

Hepatotoxicity

Hepatotoxicity with liver failure has been observed. Before starting treatment, monitor liver function tests for each treatment cycle and according to clinical indications. It should be disturbed for grade 3 or grade 4 medicine associated hepatic opposing events and discontinued if solutions are not available. In this case, do not restart Sutekast (Sunitinib Malate) if the patient has extreme changes in liver function tests or has other signs and symptoms of liver failure.

Pregnancy

Pregnant women should be informed about the potential risks to the fetus and avoid pregnancy.

Left ventricular dysfunction

Cardiac toxicity and left ventricular output were below normal lower limits. Heart failure and death has occurred - monitor the patient for signs and symptoms of heart failure.

Hypertension

High blood pressure can develop, which requires blood pressure monitoring and medication.

Hemorrhagic Events

Hemorrhagic events have occurred, including discharge associated with the tumor. Perform sequential complete blood checks and actual assessments.

Thyroid dysfunction

Thyroid dysfunction may occur. Patients with signs and indications reminiscent of hypothyroidism or hyperthyroidism should undergo laboratory tests for thyroid capacity and should be treated according to standard clinical practice.

Wound healing

Sutekast's temporary discontinuation is recommended in patients undergoing major surgery.

How to save Sutekast (Sunitinib Malate)?

It should be stored at room temperature between 20 ° C and 25 ° C. Keep it and all other medicines out of reach of children.

Materials used

Sutekast (Sunitinib Malate)

Inactive ingredients

Povidone (K-25) and magnesium stearate, Croscarmellose Sodium

Note: We are also exporting to countries: Malaysia, Indonesia, Philippines, Venezuela and Korea.
1. How to store this medicine?" Sutekast should be stored at room temperature. The ideal temperature would be between 20 degrees Celsius and 25 degrees Celsius. It is also important to keep the medicine away from children.
2. What are the different strengths of this medicine?" Sutekast is available in three different strengths:

12.5 mg capsules
25 mg capsules
50 mg capsules

3. Is this medicine available only in capsule form? Yes, Sutekast is available only in capsule form and should be consumed orally.
4. What treatment is Sutekast used for? Sutekast is used in the treatment of various types of rare cancers that include stomach cancer called a gastrointestinal stromal tumor (GST), kidney cancer called Advanced Renal Cell Carcinoma (RCC), and pancreatic cancer called Neuroendocrine pancreatic tumor (pNET).
5. What are the precautions to be taken for consuming Sutekast?Before, taking this medicine, it is important to take the following precautions:

Monitor the functions of the liver. If there are symptoms of liver failure, it is not recommended to take this medicine.
Pregnant women should not take this medicine as there is a considerable risk to the fetus.
Blood tests should be performed while on this medication to check if hemorrhagic conditions.
For patients who are about to undergo surgery, it is recommended to stop taking these medicines.

Always consult your healthcare provider before starting the dosage and if severe health issues occur while taking medicine.Sutekast comes under the category of anti-cancer drugs and is used to treat different types of cancers.
7. What are the most common side effects of consuming this medicine?"After consuming this medicine, some of the most common side effects include nausea, fatigue, diarrhea, skin-related allergies, and constipation.
8. What is the work of the active ingredients present in this medicine?There is only one main active ingredient present in this medicine called sunitinib malate, a salt that prevents the growth of cancer cells by blocking the enzymes. Therefore, it prevents the spread of cancer in the body.
9. What are the inactive ingredients present in this medicine?The inactive ingredients present in this medicine are Croscarmellose Sodium, Magnesium Stearate, and Povidone (K-25).
10. How and when to consume Sutekast medicine?" Sutekast should be consumed as prescribed by the doctor. The dosage depends on the type and severity of the disease. It is generally consumed orally with or without food.
11. Is this medicine suitable for children?No, this medicine is only for those more than 18 years of age and not recommended for children.
12. Is Sutekast recommended for pregnant women?No, Sutekast is not recommended for pregnant women as consumption of this medicine during pregnancy is risky for the fetus. Therefore, it is not recommended for women to get pregnant while taking this medicine.
13. Is there anything to be avoided while taking Sutekast?Yes, patients should not consume Sutekast with grapefruit juice. Grapefruit should be avoided completely while being on treatment with Sutekast.
14. How to get rid of the side effects, if any?" If side effects occur, it is important to inform your doctor to get further guidance on how to get rid of the side effects. In addition to that, the following measures can be taken:

Take rest and eat healthily
Drink plenty of water to stay hydrated.
Do not skip your meals
Do not rub your palms

15. How to dispose of this medication?If the medication is not required anymore, do not throw it away and keep it out of reach of children and pets. You can contact the pharmacy to enquire about medicine take-back facilities or search online about such facilities in your area.
16. What to do if I missed a dose?If a dose is missed for more than 12 hours, leave that dose and continue with the next one. If a dose is missed for less than 12 hours, then take it immediately. Ensure that you do not take an overdose.
17. What to do in case of overdose?In case of overdose, inform your healthcare provider immediately or rush to the nearest healthcare center. Call the emergency helpline number in case of emergency.
18. What is the recommended dosage of this medication?The dosage of this medicine depends on the type and severity of the disease from which the patient is affected. Therefore, do not consume this medicine without a doctor's advice.
19. What are the rare side effects of consuming this medicine?Some of the side effects that are not very common but might occur include:

Issues with hormonal glands.
Liver diseases
Cardiac problems
Internal bleeding

All the above-mentioned side effects do require treatment. Therefore, consult your doctor if any of these side effects are seen.
20. Can I consume Sutekast with other medicines?Generally, it is not recommended to consume Sutekast with other medicines as the pros and cons of doing so are not known. Consult your physician for further guidance on this.
21. Can I take this medication if I am diabetic?Sutekast may affect the blood sugar levels of the patient in case of diabetes. Therefore, it is important to monitor your blood sugar levers regularly while taking this medicine and keep your physician informed about your condition.
22. Does Sutekast affect blood pressure?Yes, consumption of Sutekast is known to increase blood pressure. If the patient experiences headache or dizziness, consult a doctor for medication to bring back the blood pressure to normal.
23. Are there any skin-related problems?Yes, the skin might turn yellow and dry. Patients might also experience rashes and blisters on the palms and soles.
24. Does Sutekast affect hair?Yes, the patient might experience hair problems like hair fall and dandruff. It is possible to overcome these problems once the medication is stopped.
25. How long should I consume this medicine?The duration of the treatment can be decided by your physician based on the severity of the disease. Sutekast is generally consumed once every day for up to 4 weeks.

zydus heptiza

Formulations associated with "zydus heptiza" (0)

Important Medical Disclaimer & Legal Notices